STRO · Sutro Biopharma, Inc. · Financials
Market Cap
$254.36M
Shares
16.58M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$102.48M
+65.2%
FY2025
Net Income
-$191.09M
+16%
FY2025
Operating Margin
-154.53%
+229.8pp
FY2025
Diluted EPS
-$22.49
+23.5%
FY2025
Operating Cash Flow
-$177.23M
+7.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $45.7M | $102.48M | $62.04M | $153.73M | $67.77M | $61.88M | $42.72M | $42.74M | $38.42M | $51.74M | $59.73M | |
| — | — | — | — | — | — | — | -$4.35M | — | — | — | |
| $144.74M | $166.42M | $252.04M | $180.43M | $137.17M | $104.4M | $76.96M | $65.61M | $54.26M | $54.64M | $43.55M | |
| $32.82M | $41.02M | $48.45M | $62.58M | $59.54M | $56M | $36.82M | $32.59M | $21.38M | $16.37M | $14.82M | |
| $6.06M | $7.32M | $7.22M | $6.82M | $5.69M | $4.84M | $4.3M | $4.78M | $4.54M | $4.99M | $5.66M | |
| $5.1M | $12.8M | — | — | — | — | — | — | — | — | — | |
| $191.75M | $260.85M | $300.5M | $243.01M | $196.72M | $160.4M | $113.78M | $98.2M | $75.64M | $71.01M | $58.37M | |
| -$146.05M | -$158.37M | -$238.45M | -$89.28M | -$128.94M | -$98.52M | -$71.06M | -$55.47M | -$37.22M | -$19.27M | $1.36M | |
| — | -154.53% | -384.34% | -58.07% | -190.26% | -159.22% | -166.32% | -129.79% | -96.89% | -37.25% | 2.28% | |
| -$139.99M | -$151.04M | -$231.24M | -$82.46M | -$123.25M | -$93.68M | -$66.76M | -$50.69M | -$32.68M | -$14.28M | $7.03M | |
| — | — | — | — | — | — | — | — | $1.62M | $612K | $0 | |
| — | — | — | — | — | — | — | — | $1.91M | -$77K | $87K | |
| -$180.73M | -$191.18M | -$225.1M | -$88.6M | -$116.7M | -$105.54M | -$32.03M | — | — | — | — | |
| -$96K | -$93K | $2.36M | $18.19M | $2.5M | $0 | $103K | $0 | $0 | $0 | — | |
| -$180.64M | -$191.09M | -$227.46M | -$106.79M | -$119.2M | -$105.54M | -$32.13M | -$119.2M | -$35.32M | -$19.69M | $1.7M | |
| — | -186.45% | -366.62% | -69.47% | -175.89% | -170.55% | -75.2% | -278.93% | -91.93% | -38.05% | 2.85% | |
| -$180.68M | -$191.11M | -$227.44M | -$106.15M | -$119.51M | -$105.98M | -$32.16M | -$55.53M | -$35.36M | -$19.67M | $1.74M | |
| USD/shares | -$17.33 | -$22.49 | -$29.40 | -$17.80 | -$23.50 | -$22.90 | -$9.90 | — | — | — | — |
| USD/shares | -$17.33 | -$22.49 | -$29.40 | -$17.80 | -$23.50 | -$22.90 | -$9.90 | — | — | — | — |
| shares | — | 8.5M | 7.74M | 6.02M | 5.07M | 4.61M | 3.26M | 2.3M | 575.89K | 44.79K | 40.77K |
| shares | — | 8.5M | 7.74M | 6.02M | 5.07M | 4.61M | 3.26M | 2.3M | 575.89K | 44.79K | 40.77K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 5.20×
EV/EBIT
—
Peer median 9.36×
P/E (TTM)
—
Peer median 11.21×
Peer medians compare against the 317 similar-size Biotechnology companies (of 532 listed).